This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Vaccine Technologies, Inc.
Drug Names(s): Peru-15
Description: CholeraGarde is an attenuated form of the bacterium Vibrio cholera.
Deal Structure: CholeraGarde was originally developed by Avant.
In March 2008, Avant Immunotherapeutics completed its acquisition of Celldex Therapeutics. In September 2008, Avant Immunotherapeutics announced that the Company will change its name to Celldex Therapeutics (CLDX) effective October 1, 2008.
In January 2009, Celldex Therapeutics announced that it entered into an exclusive license and development agreement with Vaccine Technologies (VTI). Under the license agreement, Celldex has granted a worldwide fee- and royalty-bearing exclusive license to VTI to develop and commercialize Celldex's CholeraGarde program. Financial details of the agreement with VTI were not disclosed, but include upfront license fees, milestone payments and royalties on net sales of licensed products during the term of the agreement.
Partners: Celldex Therapeutics, Inc.
Pink Sheet Chart: Weekly Trademark Review
Additional information available to subscribers only: